1: Zhou X, Wang X, Song Q, Yang H, Zhu X, Yu J, Song G, Di L, Ren J, Shao H, Lyerly HK. Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. Int J Clin Pharmacol Ther. 2015 Nov;53(11):914-22. doi: 10.5414/CP202391. doi: 10.1179/1607845412Y.0000000034. Epub 2012 Nov 19. doi: 10.1007/s00894-012-1354-y. Epub 2012 Feb 14. doi: 10.1038/srep12410. 6: Hagen B, Neverdal G, Walstad RA, Nilsen OG. Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients. Cancer Chemother Pharmacol. 1990;25(4):257-62. Cancer Lett. 1985 Jan;25(3):255-60. doi: 10.1111/j.1365-2125.2008.03321.x. Epub 2008 Nov 17. 10: Breau AP, Field L, Mitchell WM. Thiono compounds. 4. In vitro mutagenic and antineoplastic activity of TEPA and thio-TEPA. Cell Biol Toxicol. 1984 Oct;1(1):21-30.